GeoVax Announces Issuance of Malaria Vaccine Patent
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment
ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – GeoVax Labs, Inc. (Nasdaq:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to the Company’s patent application No. 17/726,254 titled “Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria.”
Related news for (GOVX)
- Breaking News: MoBot’s Latest Update as of 07/08/25 03:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/18/25 04:00 AM
- MoBot alert highlights: NASDAQ: TMC, NASDAQ: URGN, NASDAQ: NCPL, NASDAQ: EYEN, NASDAQ: GOVX (06/16/25 03:00 PM)
- MoBot’s Stock Market Highlights – 06/16/25 11:00 AM
- GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster